Southern Vitreoretinal Associates | Tallahassee, FL

Research site

(Unclaimed)

Location

2439 Care Drive, Tallahassee, Florida, United States of America

Site insights

Top conditions

Top treatments

KHK4951

Aflibercept

KSI-301

EYP-1901

Avacincaptad pegol

APL-2

MK-8748

EYE201

Galegenimab

AVD-104

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 15 total trials

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) (MALBEC)

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).Available standard (usual) treatments for NVAMD, s...

Enrolling

Choroidal Neovascularization

Age-Related Macular Degeneration

Drug: Tiespectus

Drug: Aflibercept

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting

Macular Degeneration

Geographic Atrophy of the Macula

Drug: AVD-104

Drug: Avacincaptad

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) (ARCHER II)

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.

Active, not recruiting

Geographic Atrophy

Drug: Vonaprument

Other: Sham Administration

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling

Diabetic Macular Edema (DME)

Diabetic Macular Edema

Drug: EYP-1901

Drug: Aflibercept (2.0 mg)

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (ATMOSPHERE)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Active, not recruiting

Choroidal Neovascularization

Wet Age-related Macular Degeneration

Genetic: ABBV-RGX-314

Biological: Ranibizumab (LUCENTIS®)